RIGEL PHARMACEUTICALS INC Quarterly Debt-to-equity in % from Q3 2023 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Rigel Pharmaceuticals Inc quarterly Debt-to-equity history and growth rate from Q3 2023 to Q3 2024.
  • Rigel Pharmaceuticals Inc Debt-to-equity for the quarter ending September 30, 2024 was -588 %, a 2.23% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -588 +13.4 +2.23% Sep 30, 2024
Q2 2024 -499 Jun 30, 2024
Q1 2024 -496 Mar 31, 2024
Q4 2023 -519 Dec 31, 2023
Q3 2023 -601 Sep 30, 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.